The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity
Open accessAbstract
The development of anti-drug antibodies (ADAs) following administration of biotherapeutics to patients is a vexing problem that is attracting increasing attention from pharmaceutical and biotechnology companies. This serious clinical problem is also spawning creative research into novel approaches to predict, avoid, and in some cases even reverse such deleterious immune responses. CD4+ T cells are essential players in the development of most ADAs, while memory B-cell and long-lived plasma cells amplify and maintain these responses. This review summarizes methods to predict and experimentally identify T-cell and B-cell epitopes in therapeutic proteins, with a particular focus on blood coagulation factor VIII (FVIII), whose immunogenicity is clinically significant and is the subject of intensive current research. Methods to phenotype ADA responses in humans are described, including T-cell stimulation assays, and both established and novel approaches to determine the titers, epitopes and isotypes of the ADAs themselves. Although rational protein engineering can reduce the immunogenicity of many biotherapeutics, complementary, novel approaches to induce specific tolerance, especially during initial exposures, are expected to play significant roles in future efforts to reduce or reverse these unwanted immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Surface plasmon resonance (SPR)-based epitope mapping. (A). Representative superimposed sensorgrams showing single-cycle kinetics experiments in which rFVIII-C2 protein and rFVIII-C2 variants with a single surface-exposed side chain mutated to alanine were injected at increasing concentrations over a FVIII-specific MAb captured on a biosensor [97]. Residues were flagged as potential contributors to the epitope if the kd for the FVIII-C2 mutein was >2.0X the kd for the wild-type rFVIII-C2 protein. Alanine substitutions at residues E2228, L2252, S2254, H2315 and Q2316 met this criterion in this set of experiments with MAb 1B5. Separate SPR runs (not shown here) identified residues F2196, T2197, N2198, F2200, T2202, R2220, Q2222, N2225 and K2239 as also possibly contributing to the epitope recognized by this MAb. (B). Front and back views (rotated 180°) of the FVIII C2 domain crystal structure [100], with surfaces colored to indicate the 5 partially-overlapping B-cell epitopes recognized by 11 neutralizing MAbs. The MAbs and their cognate epitopes were designated Types A, AB, B, BC and C on the basis of competition ELISA experiments. These MAbs inhibit distinct binding interactions and functions of FVIII, e.g., binding to negatively charged phospholipid surfaces, von Willebrand factor, and other proteins comprising the ‘intrinsic tenase’ complex [88]. Type A: red; Type AB: orange; Type B: yellow; Type BC: green; Type C: blue.](https://figures.cochat.ai/paper-figures/b4e508965e1343178ea7e0a607aac94f/anti-drug-antibodies-emerging-approaches-to-predict-reduce-or-reverse-figure-1.jpg)
![Figure 2 “Saturation SPR” method to characterize polyclonal anti-FVIII anti-drug antibodies (ADAs) in patient plasma samples [114]. First a high-affinity MAb specific for the FVIII A1 domain is covalently immobilized on the biosensor surface, and FVIII protein is then injected and captured by this MAb (0–700 s, not shown in figure). A plasma sample (pre-treated with caprylic acid to minimize biosensor fouling) is injected next (black arrows) followed by sequential injections of anti-hu IgG1, IgG2, IgG3 and IgG4 MAbs (red arrows), all at saturating concentrations. The vertical displacements (in RUs) may be converted to total mass at the biosensor surface following each injection, which is then converted to the total bound antibody concentration assuming an average molecular weight of 150 kDa. (A–F): The red and blue sensorgram curves depict matched plasma samples pre-incubated with (red) and without (blue) saturating (1 µM) recombinant FVIII-C2 domain protein, which will compete with the polyclonal anti-FVIII-C2 antibodies in the plasma samples. Thus, these paired SPR experiments indicate the total anti-FVIII polyclonal antibody titer, the fractions of IgG1, IgG2, IgG3 and IgG4 in the samples, and the fraction of antibodies specific for the FVIII C2 domain. Panels A-E illustrate the diverse phenotypes of the anti-FVIII IgG response in patients with allo-or autoimmune anti-FVIII antibodies. Panel F is a control experiment in which a patient-derived IgG4 monoclonal antibody specific for the FVIII C2 domain is tested in the same assay. No patient samples contained FVIII-specific IgM or IgGA (not shown). (G) The biosensor assay format is shown schematically, with the FVIII crystal structure [116] in ribbon representation.](https://figures.cochat.ai/paper-figures/bddf0305c399452d842a643eeb770d03/anti-drug-antibodies-emerging-approaches-to-predict-reduce-or-reverse-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In many cases antibodies recognize the GalNAc moiety or otherwise non-neutralizing epitopes; in-vitro neutralization does not necessarily predict in-vivo functional loss.”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The siRNA delivery platform eliminates the chance of immune responses which affect protein-based medications because no anti-drug antibodies (ADAs) developed in trial participants [53, 54].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, immature dendritic cells (iDCs) are antigen presenting cells (APCs) that often present self-antigens without stimulating T cell responses, which may allow for tolerance of peptide sequences that could be harnessed in biotherapeutic treatments.143–145”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [144]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistent LDL-C suppression among antibody-positive individuals suggests limited clinical impact of the detected antibodies [53, 54].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [54]
Experimental — accuracy not yet measuredIn the citing paper
“modulating CD4+ T cell and B cell responses may assist in reducing ADAs.144”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [144]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,983 · cited 1×
“In 1995, Clackson and Wells described “hot spots” within larger protein-protein binding interfaces that contribute most of the binding affinity [101].”
BackgroundCetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Sequence analysis of peptides bound to MHC class II molecules
Rudensky, A. Y., Preston-Hurlburt, P., Hong, S.-C., Barlow, A., & Janeway, C. A. (1991) · Nature · doi:10.1038/353622a0 · Cited by 1,075 · cited 1×
“A subset of these peptides may then be presented on an individual’s Major Histocompatability Complex (MHC), restricted to their HLA Class I and/or Class II alleles [25,26].”
BackgroundProPred: prediction of HLA-DR binding sites
Singh, H., & Raghava, G. P. S. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1236 · Cited by 841
Fundamentals and Methods for T- and B-Cell Epitope Prediction
Sanchez-Trincado, J. L., Gomez-Perosanz, M., & Reche, P. A. (2017) · Journal of Immunology Research · doi:10.1155/2017/2680160 · Cited by 674 · cited 1×
“, peptide array or phage-display results, into epitope identification approaches greatly improves success rates, compared to ab initio methods based on amino acid sequence propensities to form beta turns, or machine-learning based algorithms [42].”
Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Appella, E., Grey, H. M., & Sette, A. (1992) · Science · doi:10.1126/science.1319610 · Cited by 646
Lipid-reduction variability and antidrug-antibody formation with bococizumab
Ridker, P. M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Kim, A. M., Koenig, W., Nissen, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614062 · Cited by 369
Abshire, T., & Kenet, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00759.x · Cited by 314
Structure of the C2 domain of human factor VIII at 1.5 Å resolution
Pratt, K. P., Shen, B. W., Takeshima, K., Davie, E. W., Fujikawa, K., & Stoddard, B. L. (1999) · Nature · doi:10.1038/46601 · Cited by 308
Self-citationQuantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan
Nielsen, M., Lundegaard, C., Blicher, T., Peters, B., Sette, A., Justesen, S., Buus, S., & Lund, O. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000107 · Cited by 292
Marginal Zone, but Not Follicular B Cells, Are Potent Activators of Naive CD4 T Cells
Attanavanich, K., & Kearney, J. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.803 · Cited by 276
Banugaria, S. G., Prater, S. N., Ng, Y.-K., Kobori, J. A., Finkel, R. S., Ladda, R. L., Chen, Y.-T., Rosenberg, A. S., & Kishnani, P. S. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182174703 · Cited by 255 · cited 1×
“, a protein replacement therapy to treat monogenic diseases such as severe hemophilia A [4] or B [5], Pompe’s disease [6], etc.”
BackgroundBazan, J., Całkosiński, I., & Gamian, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21703 · Cited by 250
Ngo, J. C. K., Huang, M., Roth, D. A., Furie, B. C., & Furie, B. (2008) · Structure · doi:10.1016/j.str.2008.03.001 · Cited by 244
TLR Signalling and the Function of Dendritic Cells
Hemmi, H., & Akira, S. (2005) · Chemical Immunology and Allergy · doi:10.1159/000086657 · Cited by 241 · cited 1×
“In addition to recognizing and processing specific antigen they can also detect damage-or pathogen-associated molecular pattern molecules through toll-like receptors on their surface, activating innate immune pathways [29].”
BackgroundYank, V., Tuohy, C. V., Logan, A. C., Bravata, D. M., Staudenmayer, K., Eisenhut, R., Sundaram, V., McMahon, D., Olkin, I., McDonald, K. M., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00004 · Cited by 240
MHC Class II epitope predictive algorithms
Nielsen, M., Lund, O., Buus, S., & Lundegaard, C. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03268.x · Cited by 236
Immunogenicity of biologics in inflammatory bowel disease
Vermeire, S., Gils, A., Accossato, P., Lula, S., & Marren, A. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17750355 · Cited by 232
Plasma cell and memory B cell differentiation from the germinal center
Suan, D., Sundling, C., & Brink, R. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.03.006 · Cited by 185 · cited 1×
“In addition, splenic marginal zone B cells and macrophages serve as sentinel messengers that can encounter biotherapeutics shortly after their administration, shuttling them (in some cases) to germinal centers where the naïve immune response is initiated [81–84], and where somatic hypermutation generates B cells with…”
BackgroundIsolation and Generation of Human Dendritic Cells
Nair, S. K., Archer, G. E., & Tedder, T. F. (2012) · Current Protocols in Immunology · doi:10.1002/0471142735.im0732s99 · Cited by 170 · cited 1×
“The potential of cellular therapies employing apoptotic depletion of T cells to decrease allograft rejection is being explored [31], and ex vivo skewing of monocyte-derived DCs to a tolerogenic phenotype [32] holds promise for iDC-based therapies.”
BackgroundScandella, D., Gilbert, G., Shima, M., Nakai, H., Eagleson, C., Felch, M., Prescott, R., Rajalakshmi, K., Hoyer, L., & Saenko, E. (1995) · Blood · doi:10.1182/blood.v86.5.1811.bloodjournal8651811 · Cited by 170 · cited 1×
“Our laboratory approached B-cell epitope engineering of FVIII by first fine-mapping the epitopes recognized by neutralizing antibodies against its C-terminal C2 domain [96,97], a frequent target of neutralizing anti-FVIII ADAs [98,99].”
BackgroundRationally Engineered Therapeutic Proteins with Reduced Immunogenicity
Tangri, S., Mothé, B. R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3187 · Cited by 169 · cited 7×
“In some cases anti-Epo antibodies may provoke antibody-mediated red cell aplasia [23,24].”
BackgroundInfluentialMacrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo
van Schooten, C. J., Shahbazi, S., Groot, E., Oortwijn, B. D., van den Berg, H. M., Denis, C. V., & Lenting, P. J. (2008) · Blood · doi:10.1182/blood-2008-01-133181 · Cited by 161
Anti-Erythropoietin Antibodies and Pure Red Cell Aplasia
Rossert, J., Casadevall, N., & Eckardt, K. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000107561.59698.42 · Cited by 149 · cited 1×
“In some cases anti-Epo antibodies may provoke antibody-mediated red cell aplasia [23,24].”
BackgroundDendritic cells induce T cell proliferation to synthetic antigens under Ir gene control.
Sunshine, G. H., Katz, D. R., & Feldmann, M. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.152.6.1817 · Cited by 146 · cited 1×
“Dendritic cells (DCs) are professional APCs whose role in amplifying antigen-specific immune responses has been appreciated for decades [27,28].”
Spiegel, P. C., Jacquemin, M. G., Saint-Remy, J.-M., Stoddard, B. L., & Pratt, K. P. (2001) · Blood · doi:10.1182/blood.v98.1.13 · Cited by 140
Self-citationPathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX
Lollar, P. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00802.x · Cited by 135 · cited 1×
“In the case of anti-FVIII ADAs, it has long been known that porcine FVIII can restore hemostasis in many HA inhibitor patients, although a subset of these patients eventually develop antibodies that neutralize porcine as well as human FVIII [92,93].”
BackgroundRemoving T-cell epitopes with computational protein design
King, C., Garza, E. N., Mazor, R., Linehan, J. L., Pastan, I. H., Pepper, M., & Baker, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321126111 · Cited by 131 · cited 1×
“Additional in silico algorithms have been developed, in the public and private sectors, to predict MHCII binding and T-cell epitopes [38–42], including epitopes that may have differential effects on Tregs versus T-effectors, referred to as “Tregitopes” [43,44] and algorithms that incorporate protein structural informa…”
BackgroundImmunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131 · cited 1×
“Indeed, the prediction, experimental validation, and alteration of CD4+ T-cell epitopes are increasingly being incorporated into the workflow in the design of novel biotherapeutics [3].”
BackgroundUse of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
Joubert, M. K., Deshpande, M., Yang, J., Reynolds, H., Bryson, C. J., Fogg, M. H., Baker, M., Herskovitz, J., Goletz, T. J., Zhou, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159328 · Cited by 126 · cited 1×
“, aggregation, contamination, glycosylation, or post-translational modifications [47,48].”
Hofbauer, C. J., Whelan, S. F. J., Hirschler, M., Allacher, P., Horling, F. M., Lawo, J., Oldenburg, J., Tiede, A., Male, C., Windyga, J., et al. (2014) · Blood · doi:10.1182/blood-2014-09-598268 · Cited by 123 · cited 1×
“Sandwich ELISA assays and competitive ELISAs have been used to define isotypes, subclasses and apparent/relative affinities of anti-FVIII antibodies in HA inhibitor patient samples [110].”
MethodMazor, R., Eberle-Singh, J. A., Hu, X., Vassall, A. N., Onda, M., Beers, R., Lee, E. C., Kreitman, R. J., Lee, B., Baker, D. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405153111 · Cited by 120
Coagulant properties of hybrid human/porcine factor VIII molecules.
Lollar, P., Parker, E. T., & Fay, P. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35888-5 · Cited by 118 · cited 1×
“Building on this observation, rational modifications of B-cell epitopes in human FVIII are being pursued by several labs, including generation of hybrid human-porcine FVIII proteins [94,95].”
BackgroundJacquemin, M. G., Vantomme, V., Buhot, C., Lavend’homme, R., Burny, W., Demotte, N., Chaux, P., Peerlinck, K., Vermylen, J., Maillère, B., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1369 · Cited by 117
Antibodies to recombinant human erythropoietin causing pure red cell aplasia.
Ss, P., & Muhlfelder, T. W. (1997) · PubMed · Cited by 116
The Future of Immunotherapy: A 20-Year Perspective
Wraith, D. C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01668 · Cited by 111
Immunogenicity of therapeutic recombinant immunotoxins
Mazor, R., Onda, M., & Pastan, I. H. (2016) · Immunological Reviews · doi:10.1111/imr.12390 · Cited by 110
Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics
Jawa, V., Joubert, M. K., Zhang, Q., Deshpande, M., Hapuarachchi, S., Hall, M. P., & Flynn, G. C. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9948-4 · Cited by 104 · cited 1×
“, aggregation, contamination, glycosylation, or post-translational modifications [47,48].”
Autoantigen Microarray for High-Throughput Autoantibody Profiling in Systemic Lupus Erythematosus
Zhu, H., Luo, H., Yan, M., Zuo, X., & Li, Q. (2015) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.09.001 · Cited by 103
Onda, M., Beers, R., Xiang, L., Lee, B., Weldon, J. E., Kreitman, R. J., & Pastan, I. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102746108 · Cited by 103
Meeks, S. L., Healey, J. F., Parker, E. T., Barrow, R. T., & Lollar, P. (2007) · Blood · doi:10.1182/blood-2007-06-096842 · Cited by 101 · cited 3×
“, binding to negatively charged phospholipid surfaces, von Willebrand factor, and other proteins comprising the ‘intrinsic tenase’ complex [88].”
Backgroundvan Helden, P. M., van den Berg, H. M., Gouw, S. C., Kaijen, P. H. P., Zuurveld, M. G., Mauser‐Bunschoten, E. P., Aalberse, R. C., Vidarsson, G., & Voorberg, J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07232.x · Cited by 99 · cited 1×
“The proportions of FVIII-specific immunoglobulin isotypes in patient samples have been analyzed semi-quantitatively by ELISAs employing isotype-specific MAbs, together with engineered MAbs consisting of the variable heavy chain domain of a FVIII-specific scFv fused to the constant CH1-CH2-CH3 fragments of IgG1, IgG2,…”
MethodChristiansen, A. B., Kringelum, J. V., Hansen, C. S., Bøgh, K. L., Sullivan, E. H., Patel, J., Rigby, N. M., Eiwegger, T., Szépfalusi, Z., Masi, F. D., et al. (2015) · Scientific Reports · doi:10.1038/srep12913 · Cited by 97 · cited 1×
“The use of phage display libraries to characterize immune responses in studies of vaccines [128–131] allergy [121,127,132] and autoimmunity [133] is highly analogous to profiling of alloimmune responses to a biotherapeutic.”
BackgroundWeldon, J. E., Xiang, L., Zhang, J., Beers, R., Walker, D. A., Onda, M., Hassan, R., & Pastan, I. H. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0336 · Cited by 93
Mazor, R., Vassall, A. N., Eberle-Singh, J. A., Beers, R., Weldon, J. E., Venzon, D. J., Tsang, K. Y., Benhar, I., & Pastan, I. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218138109 · Cited by 91
Deisenhammer, F. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00003 · Cited by 87
James, E. A., Kwok, W. W., Ettinger, R. A., Thompson, A. R., & Pratt, K. P. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02762.x · Cited by 87 · cited 1×
“The observed narrow epitope and TCR repertoire documented in this subject suggest that clonal deletion and anergy contribute to peripheral tolerance, although even some successfully tolerized patients continue to circulate FVIII-specific T-effectors [64], with their tolerance likely due to Treg dampening of the immune…”
BackgroundSelf-citationImmunogenicity of biologic therapies: causes and consequences
Boehncke, W., & Brembilla, N. C. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1468753 · Cited by 87 · cited 1×
“Similarly, the need for standardized assays utilizing predictive biomarkers of ADAs against any biologics to improve clinical decision-making has been pointed out [144].”
BackgroundIdentification of HLA-DRB1 association to adalimumab immunogenicity
Liu, M., Degner, J. F., Davis, J. W., Idler, K. B., Nader, A. M., Mostafa, N. M., & Waring, J. F. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195325 · Cited by 86
Healey, J. F., Barrow, R. T., Tamim, H. M., Lubin, I. M., Shima, M., Scandella, D. H., & Lollar, P. (1998) · Blood · doi:10.1182/blood.v92.10.3701 · Cited by 85
Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85 · cited 1×
“Protein engineering and process control improvements to reduce aggregation propensity can also reduce potential immunogenicity [80].”
BackgroundAnalysis of Protein Interactions by Surface Plasmon Resonance
Drescher, D. G., Selvakumar, D., & Drescher, M. J. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.07.003 · Cited by 82 · cited 2×
““Saturation SPR” method to characterize polyclonal anti-FVIII anti-drug antibodies (ADAs) in patient plasma samples [114].”
BackgroundMethodYeung, V. P., Chang, J., Miller, J., Barnett, C., Stickler, M. M., & Harding, F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6658 · Cited by 81 · cited 1×
“Epitope de-immunization strategies have shown promise in reducing the immunogenicity of other sequence-modified proteins including recombinant immunotoxins used for cancer therapies [65–72], interferon-β [73], interferon-α [72], staphylokinase [74], β-lactamase [75], Epo [33,37], and monoclonal antibodies [37,76].”
BackgroundEffect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo
Moise, L., Song, C. H., Martin, W. D., Tassone, R., Groot, A. S. D., & Scott, D. W. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.11.010 · Cited by 80
Nagata, S., & Pastan, I. H. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.07.014 · Cited by 80
Ettinger, R. A., James, E. A., Kwok, W. W., Thompson, A. R., & Pratt, K. P. (2009) · Blood · doi:10.1182/blood-2009-01-200725 · Cited by 79
Self-citationMacdougall, I. C., Casadevall, N., Locatelli, F., Combe, C., London, G. M., Paolo, S. D., Kribben, A., Fliser, D., Messner, H. A., McNeil, J. J., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu297 · Cited by 79 · cited 1×
“In some cases anti-Epo antibodies may provoke antibody-mediated red cell aplasia [23,24].”
Backgroundvan Haren, S. D., Herczenik, E., ten Brinke, A., Mertens, K., Voorberg, J., & Meijer, A. B. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002246 · Cited by 77
Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A
Zerra, P. E., Cox, C. L., Baldwin, W. H., Patel, S. R., Arthur, C. M., Lollar, P., Meeks, S. L., & Stowell, S. R. (2017) · Blood · doi:10.1182/blood-2017-05-782912 · Cited by 75
Navarrete, A., Dasgupta, S., Delignat, S., Caligiuri, G., Christophe, O. D., Bayry, J., Nicoletti, A., Kaveri, S. V., & Lacroix‐Desmazes, S. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03571.x · Cited by 74
Steinitz, K. N., van Helden, P. M., Binder, B., Wraith, D. C., Unterthurner, S., Hermann, C., Schuster, M., Ahmad, R. U., Weiller, M., Lubich, C., et al. (2012) · Blood · doi:10.1182/blood-2011-08-374645 · Cited by 74
Bartelds, G. M., de Groot, E. R., Nurmohamed, M. T., Hart, M. H. L., van Eede, P. H., Wijbrandts, C. A., Crusius, J. B. A., Dijkmans, B. A. C., Tak, P. P., Aarden, L. A., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3208 · Cited by 71
Harding, F., Liu, A. D., Stickler, M. M., Razo, O. J., Chin, R., Faravashi, N., Viola, W., Graycar, T., Yeung, V. P., Aehle, W., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0189 · Cited by 68
Zhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Casina, V. C., Hu, W., Mao, J., Lu, R., Hanby, H. A., Pickens, B., Kan, Z.-Y., Lim, W. K., Mayne, L. C., Ostertag, E. M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512561112 · Cited by 63 · cited 1×
“The use of phage display libraries to characterize immune responses in studies of vaccines [128–131] allergy [121,127,132] and autoimmunity [133] is highly analogous to profiling of alloimmune responses to a biotherapeutic.”
BackgroundHarnessing the properties of dendritic cells in the pursuit of immunological tolerance
Horton, C. G., Shanmugarajah, K., & Fairchild, P. J. (2017) · Biomedical Journal · doi:10.1016/j.bj.2017.01.002 · Cited by 63 · cited 1×
“Immature, tolerogenic DCs (iDCs) are a distinct DC subset that can efficiently present peptides without promoting strong co-stimulation of naïve T cells; iDCs secrete low levels of interleukin (IL)-12 and higher levels of IL-10 and TGF-β and are thought to contribute to tolerance via anergy and deletion of T-effectors…”
BackgroundEngineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62
Mahlangu, J. N., Weldingh, K. N., Lentz, S. R., Kaicker, S. M., Karim, F. A., Matsushita, T., Recht, M., Tomczak, W., Windyga, J., Ehrenforth, S., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13141 · Cited by 60
Ettinger, R. A., James, E. A., Kwok, W. W., Thompson, A. R., & Pratt, K. P. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2008.01905.x · Cited by 57
Self-citationEngineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells
Dawson, N. A. J., Vent‐Schmidt, J., & Levings, M. K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01460 · Cited by 57
Guo, D., Key, N. S., Conti‐Fine, B. M., & Hu, G. (2007) · Thrombosis and Haemostasis · doi:10.1160/th06-09-0519 · Cited by 56
Design and engineering of deimmunized biotherapeutics
Griswold, K. E., & Bailey‐Kellogg, C. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.06.003 · Cited by 54 · cited 1×
“Additional in silico algorithms have been developed, in the public and private sectors, to predict MHCII binding and T-cell epitopes [38–42], including epitopes that may have differential effects on Tregs versus T-effectors, referred to as “Tregitopes” [43,44] and algorithms that incorporate protein structural informa…”
BackgroundEmerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies
Partridge, M. A. K., Purushothama, S., Elango, C., & Lu, Y. (2016) · Journal of Immunology Research · doi:10.1155/2016/6262383 · Cited by 52
Okita, D. K., Diethelm-Okita, B. M., Conti‐Fine, B. M., Pratt, K. P., Qian, J., Ellaban, E., & Scott, D. W. (2004) · Thrombosis and Haemostasis · doi:10.1160/th03-12-0755 · Cited by 49
Self-citationNonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
Meeks, S. L., Healey, J. F., Parker, E. T., Barrow, R. T., & Lollar, P. (2008) · Blood · doi:10.1182/blood-2008-01-132639 · Cited by 49
Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII
Barrow, R. T., & Lollar, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02135.x · Cited by 47 · cited 1×
“In the case of anti-FVIII ADAs, it has long been known that porcine FVIII can restore hemostasis in many HA inhibitor patients, although a subset of these patients eventually develop antibodies that neutralize porcine as well as human FVIII [92,93].”
BackgroundStephenson, K. E., Neubauer, G. H., Reimer, U., Pawlowski, N., Knaute, T., Zerweck, J., Korber, B., & Barouch, D. H. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.11.006 · Cited by 47 · cited 1×
“Such array analyses have proven valuable in vaccine studies [118,119] and in profiling of autoimmune disorders, infections and cancer [117], and they may also be applied to characterize ADAs [120].”
BackgroundKamaté, C., Lenting, P. J., van den Berg, H. M., & Mutis, T. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02336.x · Cited by 46
Analytical Protein Microarrays: Advancements Towards Clinical Applications
Sauer, U. (2017) · Sensors · doi:10.3390/s17020256 · Cited by 46
Sevy, A. M., Healey, J. F., Deng, W., Spiegel, P. C., Meeks, S. L., & Li, R. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12433 · Cited by 45
Meunier, S., Menier, C., Marcon, E., Lacroix‐Desmazes, S., & Maillère, B. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017008706 · Cited by 45
James, E. A., van Haren, S. D., Ettinger, R. A., Fijnvandraat, K., Liberman, J. A., Kwok, W. W., Voorberg, J., & Pratt, K. P. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04202.x · Cited by 44
Self-citationMazor, R., Onda, M., Park, D., Addissie, S., Xiang, L., Zhang, J., Hassan, R., & Pastan, I. H. (2016) · Oncotarget · doi:10.18632/oncotarget.9171 · Cited by 44
The diversity of the immune response to the A2 domain of human factor VIII
Markovitz, R. C., Healey, J. F., Parker, E. T., Meeks, S. L., & Lollar, P. (2013) · Blood · doi:10.1182/blood-2012-09-456582 · Cited by 43
Protein microarray applications: Autoantibody detection and posttranslational modification
Atak, A., Mukherjee, S., Jain, R., Gupta, S., Singh, V. A., Gahoi, N., Manubhai, K. P., & Srivastava, S. (2016) · PROTEOMICS · doi:10.1002/pmic.201600104 · Cited by 43
Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling
Plaisance, S., Vanderlick, K., Vandervoort, P., Brepoels, K., Collen, D., Maeyer, M. D., & Warmerdam, P. A. M. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613064 · Cited by 42 · cited 1×
“Epitope de-immunization strategies have shown promise in reducing the immunogenicity of other sequence-modified proteins including recombinant immunotoxins used for cancer therapies [65–72], interferon-β [73], interferon-α [72], staphylokinase [74], β-lactamase [75], Epo [33,37], and monoclonal antibodies [37,76].”
BackgroundHu, G. L., Okita, D. K., & Conti‐Fine, B. M. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00918.x · Cited by 42
Kahle, J., Orlowski, A., Stichel, D., Healey, J. F., Parker, E. T., Jacquemin, M. G., Krause, M., Tiede, A., Schwabe, D., Lollar, P., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751347 · Cited by 42
Pautard, B., d’Oiron, R., TE, V. L. T., Lavend’homme, R., Saint‐Remy, J., Peerlinck, K., & Jacquemin, M. G. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04267.x · Cited by 41 · cited 1×
“The observed narrow epitope and TCR repertoire documented in this subject suggest that clonal deletion and anergy contribute to peripheral tolerance, although even some successfully tolerized patients continue to circulate FVIII-specific T-effectors [64], with their tolerance likely due to Treg dampening of the immune…”
BackgroundHavenith, H., Kern, K., Rautenberger, P., Spiegel, H., Szardenings, M., Ueberham, E., Lehmann, J., Buntru, M., Vogel, S., Treudler, R., et al. (2016) · Biotechnology Journal · doi:10.1002/biot.201600441 · Cited by 41 · cited 1×
“The use of phage display libraries to characterize immune responses in studies of vaccines [128–131] allergy [121,127,132] and autoimmunity [133] is highly analogous to profiling of alloimmune responses to a biotherapeutic.”
BackgroundPhage display—A powerful technique for immunotherapy
Bazan, J., Całkosiński, I., & Gamian, A. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21704 · Cited by 39
Nguyen, P.-C., Lewis, K. B., Ettinger, R. A., Schuman, J. T., Lin, J. C., Healey, J. F., Meeks, S. L., Lollar, P., & Pratt, K. P. (2014) · Blood · doi:10.1182/blood-2013-09-527275 · Cited by 38 · cited 4×
“Representative superimposed sensorgrams showing single-cycle kinetics periments in which rFVIII-C2 protein and rFVIII-C2 variants with a single surface-exposed side chain mutated to alanine were injected at increasing concentrations over a FVIII-specific MAb captured on a biosensor [97].”
BackgroundInfluentialSelf-citationWalter, J. D., Werther, R. A., Brison, C. M., Cragerud, R. K., Healey, J. F., Meeks, S. L., Lollar, P., & Spiegel, P. C. (2013) · Blood · doi:10.1182/blood-2013-08-519124 · Cited by 38
Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A
Chaves, D. G., Belisário, A. R., Castro, G., Santoro, M. M., & Rodrigues, C. (2010) · International Journal of Immunogenetics · doi:10.1111/j.1744-313x.2009.00893.x · Cited by 38
Turner, K. B., Naciri, J. N., Liu, J. L., Anderson, G. P., Goldman, E. R., & Zabetakis, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149393 · Cited by 38
Cohen, T. S. D., Moise, L., Ardito, M. T., Martin, W. D., & Groot, A. S. D. (2010) · BioMed Research International · doi:10.1155/2010/961752 · Cited by 37 · cited 1×
“Additional in silico algorithms have been developed, in the public and private sectors, to predict MHCII binding and T-cell epitopes [38–42], including epitopes that may have differential effects on Tregs versus T-effectors, referred to as “Tregitopes” [43,44] and algorithms that incorporate protein structural informa…”
BackgroundZarei, M., Nezafat, N., Rahbar, M. R., Negahdaripour, M., Sabetian, S., Morowvat, M. H., & Ghasemi, Y. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1431151 · Cited by 36 · cited 1×
“, with recent application to recombinant arginine deiminase (a cancer biotherapeutic) [137].”
BackgroundMazor, R., Zhang, J., Xiang, L., Addissie, S., Awuah, P. K., Beers, R., Hassan, R., & Pastan, I. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0532 · Cited by 35
Blumberg, R. S., Lillicrap, D., & the IgG Fc Immune Tolerance Group (2018) · Blood · doi:10.1182/blood-2017-12-822908 · Cited by 35
Circumventing immunogenicity in the development of therapeutic antibodies.
Holgate, R., & Baker, M. (2009) · PubMed · Cited by 33
Ettinger, R. A., Paz, P., James, E. A., Gunasekera, D., Aswad, F., Thompson, A. R., Matthews, D. C., & Pratt, K. P. (2016) · Blood · doi:10.1182/blood-2015-11-682468 · Cited by 33 · cited 1×
“Our laboratory utilized MHCII tetramers loaded with FVIII peptides to query the T-cell response of a severe HA subject with an F8 gene deletion mutation and a persistent high-titer inhibitor [62].”
MethodSelf-citationEpitope Mapping by Phage Display
Moreira, G. M. S. G., Fühner, V., & Hust, M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7447-4_28 · Cited by 33
Lollar, P., Healey, J. F., Barrow, R. T., & Parker, E. T. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1277-6_6 · Cited by 32 · cited 1×
“, a protein replacement therapy to treat monogenic diseases such as severe hemophilia A [4] or B [5], Pompe’s disease [6], etc.”
BackgroundApplication of phage peptide display technology for the study of food allergen epitopes
Chen, X., & Dreskin, S. C. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600568 · Cited by 30 · cited 1×
“The use of phage display libraries to characterize immune responses in studies of vaccines [128–131] allergy [121,127,132] and autoimmunity [133] is highly analogous to profiling of alloimmune responses to a biotherapeutic.”
BackgroundEttinger, R. A., Liberman, J. A., Gunasekera, D., Puranik, K., James, E. A., Thompson, A. R., & Pratt, K. P. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017013482 · Cited by 30 · cited 1×
“Indeed, strategic amino acid substitutions in this FVIII epitope at MHCII anchor positions P1 and P4 abrogated proliferation of the patient-derived clones and lines without compromising the protein’s specific activity [63].”
BackgroundSelf-citationLimited Promiscuity of HLA-DRB1 Presented Peptides Derived of Blood Coagulation Factor VIII
van Haren, S. D., Wroblewska, A., Herczenik, E., Kaijen, P. H. P., Rumińska, A., ten Brinke, A., Meijer, A. B., & Voorberg, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080239 · Cited by 29
Challenges in the pursuit of immune tolerance
Nepom, G. T., Clair, E. W. S., & Turka, L. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01003.x · Cited by 29
TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity
Mahlangu, J. N., Paz, P., Hardtke, M., Aswad, F., & Schroeder, J. (2016) · Haemophilia · doi:10.1111/hae.12994 · Cited by 28
Jardim, L. L., Chaves, D. G., Silveira-Cassette, A. C. D. O., Silva, A. C. S. E., Santana, M. P., Cerqueira, M., Prezotti, A., Lorenzato, C. S., Franco, V. K. B., van der Bom, J. G., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14799 · Cited by 28 · cited 1×
“In addition to characterizing the ADAs themselves, immunoprofiling of patient plasma samples has demonstrated differences in circulating cytokines and in types of microparticles between naïve HA subjects, age-matched healthy controls [138] and HA subjects with and without a neutralizing ADA response [139–143].”
BackgroundPopulation-specific design of de-immunized protein biotherapeutics
Schubert, B., Schärfe, C., Dönnes, P., Hopf, T. A., Marks, D. S., & Kohlbacher, O. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005983 · Cited by 27 · cited 1×
“Additional in silico algorithms have been developed, in the public and private sectors, to predict MHCII binding and T-cell epitopes [38–42], including epitopes that may have differential effects on Tregs versus T-effectors, referred to as “Tregitopes” [43,44] and algorithms that incorporate protein structural informa…”
BackgroundPeyron, I., Hartholt, R. B., Pedró-Cos, L., van Alphen, F. P. J., ten Brinke, A., Lardy, N. M., Meijer, A. B., & Voorberg, J. (2017) · Haematologica · doi:10.3324/haematol.2017.175083 · Cited by 27
Mufarrege, E. F., Giorgetti, S., Etcheverrigaray, M., Terry, F. E., Martin, W. D., & Groot, A. S. D. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.01.003 · Cited by 25
Dhanda, S. K., Grifoni, A., Pham, J. W., Vaughan, K. C., Sidney, J., Peters, B., & Sette, A. (2017) · Immunology · doi:10.1111/imm.12816 · Cited by 25 · cited 7×
“In some cases anti-Epo antibodies may provoke antibody-mediated red cell aplasia [23,24].”
BackgroundInfluentialChaves, D. G., Velloso‐Rodrigues, C., de Oliveira, C. A., Teixeira‐Carvalho, A., Santoro, M. M., & Martins‐Filho, O. A. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04258.x · Cited by 24
Santagostino, E., Escobar, M. A., Ozelo, M. C., Solimeno, L. P., Arkhammar, P. O. G., Lee, H. Y., Rosu, G. N., & Giangrande, P. L. F. (2015) · Blood Reviews · doi:10.1016/s0268-960x(15)30003-5 · Cited by 24
Lewis, K. B., Hughes, R. J., Epstein, M. S., Josephson, N. C., Kempton, C. L., Kessler, C. M., Key, N. S., Howard, T. E., Kruse‐Jarres, R., Lusher, J. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061120 · Cited by 24 · cited 1×
“developed a novel SPR-based assay to quantify both the total anti-FVIII antibody titers, and the amount of each subclass comprising this total [114], exploiting the fact that the change in Response Units (RUs) upon saturation binding of an antibody to a ligand immobilized on a biosensor chip is easily converted to the…”
BackgroundSelf-citationHomann, A., Röckendorf, N., Kromminga, A., Frey, A., Platts‐Mills, T. A. E., & Jappe, U. (2017) · Theranostics · doi:10.7150/thno.20654 · Cited by 24 · cited 1×
“Such array analyses have proven valuable in vaccine studies [118,119] and in profiling of autoimmune disorders, infections and cancer [117], and they may also be applied to characterize ADAs [120].”
BackgroundEngineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs
Sicard, A., Levings, M. K., & Scott, D. W. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14747 · Cited by 24
Pathogen-specific deep sequence-coupled biopanning: A method for surveying human antibody responses
Frietze, K. M., Pascale, J. M., Moreno, B. A., Chackerian, B., & Peabody, D. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171511 · Cited by 23
Cytokine profile and FVIII inhibitors development in haemophilia A
de Oliveira, C. A., Velloso‐Rodrigues, C., Machado, F. C. J., de Carvalho, B. N., Gentz, S., Martins‐Filho, O. A., & Chaves, D. G. (2013) · Haemophilia · doi:10.1111/hae.12096 · Cited by 22
Walter, J. D., Werther, R. A., Polozova, M. S., Pohlman, J., Healey, J. F., Meeks, S. L., Lollar, P., & Spiegel, P. C. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.424564 · Cited by 22
Franchini, M., Santoro, C., & Coppola, A. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-02-0116 · Cited by 22 · cited 1×
“, a protein replacement therapy to treat monogenic diseases such as severe hemophilia A [4] or B [5], Pompe’s disease [6], etc.”
BackgroundAnalysis of Factor VIII Inhibitors Using Hybrid Human/Porcine Factor VIII
Lollar, P. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657605 · Cited by 22 · cited 1×
“Building on this observation, rational modifications of B-cell epitopes in human FVIII are being pursued by several labs, including generation of hybrid human-porcine FVIII proteins [94,95].”
BackgroundMazor, R., Kaplan, G., Park, D., Jang, Y., Lee, F., Kreitman, R. J., & Pastan, I. H. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.01.003 · Cited by 22
Ambati, A., Valentini, D., Montomoli, E., Lapini, G., Biuso, F., Wenschuh, H., Magalhaes, I., & Maeurer, M. J. (2015) · Immunology · doi:10.1111/imm.12448 · Cited by 20 · cited 1×
“Such array analyses have proven valuable in vaccine studies [118,119] and in profiling of autoimmune disorders, infections and cancer [117], and they may also be applied to characterize ADAs [120].”
BackgroundLim, L. C. (2005) · Hematology · doi:10.1080/10245330400026154 · Cited by 20 · cited 1×
“, erythropoietin (Epo) [19,20] and interferon-β [21,22], has been shown to provoke unwanted, rare, but potentially serious immunogenicity.”
BackgroundKicking off adaptive immunity: the discovery of dendritic cells
Katsnelson, A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.2037fta · Cited by 19 · cited 1×
“Dendritic cells (DCs) are professional APCs whose role in amplifying antigen-specific immune responses has been appreciated for decades [27,28].”
BackgroundYi, H., Chae, C.-S., So, J., Tzartos, S. J., Souroujon, M. C., Fuchs, S., & Im, S. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.08.264 · Cited by 18 · cited 1×
“B-cell epitope removal has also shown promise in promoting tolerance to autoantigens such as the nicotinic acetylcholine receptor [108].”
BackgroundLin, J. C., Ettinger, R. A., Schuman, J. T., Zhang, A.-H., Wamiq-Adhami, M., Nguyen, P.-C., Nakaya-Fletcher, S. M., Puranik, K., Thompson, A. R., & Pratt, K. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116577 · Cited by 18 · cited 2×
“Our laboratory approached B-cell epitope engineering of FVIII by first fine-mapping the epitopes recognized by neutralizing antibodies against its C-terminal C2 domain [96,97], a frequent target of neutralizing anti-FVIII ADAs [98,99].”
BackgroundSelf-citationEmerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A
Castaman, G., Eckhardt, C. L., van Velzen, A. S., Linari, S., & Fijnvandraat, K. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1571309 · Cited by 18 · cited 1×
“Up to 1 in 3 severe HA patients develops neutralizing ADAs, referred to by hematologists as “inhibitors”, and even patients with mild or moderate HA resulting from missense mutations may develop an inhibitor [49].”
BackgroundBrier, S., Mignon, M. L., Jain, K., Lebrun, C., Peurois, F., Kellenberger, C., Floch, V. B., Mascarell, L., Nony, E., & Moingeon, P. E. (2017) · Allergy · doi:10.1111/all.13364 · Cited by 18 · cited 2×
“B-cell epitopes may be mapped at high resolution by determining crystal structures of antigen-antibody complexes, and by hydrogen-deut rium (H/D) exchange/mass spectrom try to identify antigen-antibody interfaces that are protected from solvent [86,87], and hence from H/D exchange.”
BackgroundHrdinová, J., Verbij, F. C., Kaijen, P. H. P., Hartholt, R. B., van Alphen, F. P. J., Lardy, N. M., ten Brinke, A., Vanhoorelbeke, K., Hindocha, P., Groot, A. S. D., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.179119 · Cited by 18 · cited 1×
“Similar methods have been used to map autoimmune epitopes in the blood protein ADAMTS13 [61].”
MethodB-cell memory against factor VIII
Reipert, B. M. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.01.003 · Cited by 16
Silveira, A. C. O., Santana, M. P., Ribeiro, I. G., Chaves, D. G., & Martins‐Filho, O. A. (2015) · BMC Hematology · doi:10.1186/s12878-014-0019-8 · Cited by 15
Innovating immune tolerance induction for haemophilia
Batsuli, G. M., Meeks, S. L., Herzog, R. W., & Lacroix‐Desmazes, S. (2016) · Haemophilia · doi:10.1111/hae.12989 · Cited by 15
Peptide Microarrays for Medical Applications in Autoimmunity, Infection, and Cancer
Grötzinger, C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3037-1_16 · Cited by 13 · cited 2×
“Such array analyses have proven valuable in vaccine studies [118,119] and in profiling of autoimmune disorders, infections and cancer [117], and they may also be applied to characterize ADAs [120].”
BackgroundMonitoring Phage Biopanning by Next-Generation Sequencing
Vaisman‐Mentesh, A., & Wine, Y. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7447-4_26 · Cited by 13
Kuang, R., Perruche, S., & Chen, W. (2015) · Cell & Bioscience · doi:10.1186/s13578-015-0019-9 · Cited by 12 · cited 2×
“The potential of cellular therapies employing apoptotic depletion of T cells to decrease allograft rejection is being explored [31], and ex vivo skewing of monocyte-derived DCs to a tolerogenic phenotype [32] holds promise for iDC-based therapies.”
BackgroundIdentification of a conserved linear B-cell epitope in the Staphylococcus aureus GapC protein
Wang, M., Wei, Y., Yu, W., Wang, L., Zhai, L., Li, X., Wang, X., Zhang, H., Feng, Z., Yu, L., et al. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.03.007 · Cited by 12
PuLSE: Quality control and quantification of peptide sequences explored by phage display libraries
Shave, S., Mann, S., Koszela, J., Kerr, A. R. W., & Auer, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193332 · Cited by 12
Huang, T., Mathieu, M. A., Lee, S., Wang, X., Kee, Y. S., Bevers, J. J., Ciferri, C., Estavez, A., Wong, M., Chiang, N., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000165 · Cited by 11 · cited 1×
“Epitope de-immunization strategies have shown promise in reducing the immunogenicity of other sequence-modified proteins including recombinant immunotoxins used for cancer therapies [65–72], interferon-β [73], interferon-α [72], staphylokinase [74], β-lactamase [75], Epo [33,37], and monoclonal antibodies [37,76].”
BackgroundMICHALSKA, M., Schultze-Seemann, S., Kuckuck, I., & Wolf, P. (2018) · Anticancer Research · doi:10.21873/anticanres.12192 · Cited by 11
Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening
Miller, C. H., Rice, A. S., Boylan, B., Payne, A. B., Kelly, F. M., Escobar, M. A., Gill, J. C., Leissinger, C., & Soucie, J. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24104 · Cited by 9
From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance
Scott, D. W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01576 · Cited by 9
Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?
Groot, A. S. D. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2013.858602 · Cited by 7 · cited 1×
“Additional in silico algorithms have been developed, in the public and private sectors, to predict MHCII binding and T-cell epitopes [38–42], including epitopes that may have differential effects on Tregs versus T-effectors, referred to as “Tregitopes” [43,44] and algorithms that incorporate protein structural informa…”
BackgroundAnti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile
Danese, S., & Fiorino, G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180514100204 · Cited by 6
Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries
Schmidt, A., Brettschneider, K., Kahle, J., Orlowski, A., Becker‐Peters, K., Stichel, D., Schulze, J., Braner, M., Tampé, R., Schwabe, D., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-12-0925 · Cited by 4 · cited 1×
“, by phage display, and employed to block neutralizing polyclonal antibodies that patients develop against therapeutic proteins [109].”
BackgroundProteomic Monitoring of B Cell Immunity
Ewaisha, R., & Anderson, K. S. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_6 · Cited by 3 · cited 1×
“, but ongoing technical advances indicate that such proteomics analyses will increasingly play a role in clinical diagnostics and epitope mapping applications [125].”
Background
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Jarantow, S. W., Pisors, E. D., & Chiu, M. L. (2023) · Current Protocols · doi:10.1002/cpz1.801 · Cited by 161
“Immunogenicity assessments such as anti-drug antibody assays (Adan et al. 2016) detect immune responses against a therapeutic, which can be immunogenic and/or neutralizing, and significantly affect PK/PD behavior (Pratt, 2018; Song et al., 2016).”
BackgroundImmunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Carter, P. J., & Quarmby, V. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01051-x · Cited by 122
“For example, a substantial proportion of patients with haemophilia A develop neutralizing ADAs — ‘inhibitors’ in the lexicon of haematolo-gists — when treated with replacement clotting factors 45 .”
Assessing developability early in the discovery process for novel biologics
Fernández‐Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G. R., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 108
Metadata
- Authors
- Pratt, K. P.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Corresponding author
- Pratt, Kathleen P.
- ORCID
- Pratt, Kathleen P.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2018-05-31
- Volume
- 7
- Issue
- 2
- Pages
- 19
- ISSN
- 2073-4468 (ISSN-L)
- PMC
- PMC6698869
- OpenAlex
- W2806365218
- Cited by
- 96
- References
- 149
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 16 · 2021: 15 · 2020: 19 · 2019: 5 · 2018: 1
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Antibodies (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (1R01 HL 130448)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- anti-drug antibodies, CD4+ T cells, memory B cells, long-lived plasma cells, epitope prediction, rational protein design, immune tolerance induction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.